Tuberculosis reactivation demonstrated by choroiditis and inflammatory choroidal neovascular membrane in a patient treated with immune checkpoint inhibitors for malignant mucosal melanoma

被引:0
|
作者
Murphy, Melissa L. [1 ]
Rogers, Duncan [1 ]
机构
[1] Mater Misericordiae Univ Hosp, Sch Med & Med Sci, Eccles St Dublin 7, Dublin, Ireland
关键词
Immune checkpoint inhibitors; Uveitis; Tuberculosis; Serpiginous-like Choroiditis; Choroidal Neovascular Membrane; Malignant Melanoma; NIVOLUMAB; UVEITIS;
D O I
10.1186/s12348-023-00374-x
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PurposeTo describe a complex case of ocular tuberculosis reactivation with anterior uveitis, choroiditis and inflammatory choroidal neovascular membrane (CNVM) following immune checkpoint inhibitor (ICPI) treatment of malignant mucosal melanoma.MethodsA retrospective collection of medical history, clinical findings and multimodal imaging with literature review of the topic was conducted.ResultsA 52-year-old Romanian female developed reduced vision and photophobia after three cycles of ICPI therapy comprised of ipilimumab and nivolumab. Bilateral anterior uveitis, multiple left eye choroidal lesions and a CNVM were confirmed using slit-lamp examination with ancillary multimodal imaging. Retinal changes in the right eye as well as a history of previously treated posterior uveitis and high-risk ethnicity increased clinical suspicion for ocular tuberculosis (TB) reactivation. The diagnosis was confirmed by TB positivity on polymerase chain reaction (PCR) analysis of lung aspirate followed by significant clinical improvement on systemic anti-tubercular therapy (ATT), systemic steroids and anti-vascular endothelial growth factor (VEGF) therapy.ConclusionsICPIs can cause a myriad of ocular issues, both by primary immunomodulatory effects as well as secondary reactivation of latent disease.
引用
收藏
页数:7
相关论文
共 25 条
  • [21] Recurrent CK-Increase in a 28-year-old Patient with metastatic malignant Melanoma by BRAF/MEK Therapy and Immune Checkpoint-Inhibitors Therapy
    Henning, B.
    Bradfisch, F.
    Stege, H.
    Saloga, J.
    Grabbe, S.
    Loquai, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 33 - 34
  • [22] Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review
    Ou, Yan
    Liang, Shufang
    Gao, Qiangqiang
    Shang, Yongran
    Liang, Junfang
    Zhang, Weitao
    Liu, Sha
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [23] Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4
    Seban, Romain-David
    Moya-Plana, Antoine
    Antonios, Lara
    Yeh, Randy
    Marabelle, Aurelien
    Deutsch, Eric
    Schwartz, Lawrence H.
    Gomez, Ruth Gabriela Herrera
    Saenger, Yvonne
    Robert, Caroline
    Ammari, Samy
    Dercle, Laurent
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (10) : 2301 - 2312
  • [24] Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4
    Romain-David Seban
    Antoine Moya-Plana
    Lara Antonios
    Randy Yeh
    Aurélien Marabelle
    Eric Deutsch
    Lawrence H. Schwartz
    Ruth Gabriela Herrera Gómez
    Yvonne Saenger
    Caroline Robert
    Samy Ammari
    Laurent Dercle
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2301 - 2312
  • [25] Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI)
    Svedman, F. Costa
    Yang, M.
    Tuominen, R.
    Brage, S. E.
    Holom, V.
    ANNALS OF ONCOLOGY, 2019, 30